Vepdegestrant Receives FDA Approval — A New Chapter in ESR1-Mutant Breast Cancer
In this article
On 1 May 2026, approval from the US Food and Drug Administration (FDA) for vepdegestrant (Veppanu, Arvinas/Pfizer) was granted for adults with estrogen receptor-positive (ER+), HER2-negative, advanced or metastatic breast cancer harboring an ESR1 mutation, whose disease had progressed after at least one endocrine therapy.
In clinical oncology, this is the first FDA-approved PROTAC drug; the clinical realization of the 25-year academic journey of targeted protein degradation (TPD) technology.
On the same day, to identify patients with an ESR1 mutation, the FDA also granted Guardant360 CDxapproval as a companion diagnostic — so the drug and the test entered clinical practice as a pair.
And in the VERITAC-2 phase 3 trial, in progression-free survival compared with fulvestrant, more than twice the benefit was demonstrated by this oral drug, marking the beginning of the transition "from injection to tablet" in the treatment of ER+ metastatic breast cancer.
A Molecule Dragging a Protein to a Trash Bin
The last 25 years of modern oncology have been defined by small-molecule inhibitors : gefitinib blocks EGFR's active site; imatinib makes the BCR-ABL kinase unable to function; trastuzumab deprives HER2 of signaling. They all work on the same basic principle — block the protein, but leave it in place. A PROTAC, however, represents an entirely different paradigm: rather than blocking the protein, it hands it over to the cell's own waste-collection system.
The abbreviation "PROTAC", from the words PROteolysis TArgeting Chimera, is formed from their initial letters. In Turkish, the equivalent can be expressed as "proteolizi hedefleyen kimera" (a chimera targeting proteolysis). As their name suggests, these are two-headed molecules:
When a PROTAC molecule enters the cell, one end attaches to the target protein (for vepdegestrant: the estrogen receptor), while the other attaches to an E3 ubiquitin ligase, a component of the cell's own protein degradation system. It physically brings the two proteins together; the ubiquitin ligase then attaches ubiquitin molecules to the target protein as small "remove and dispose" tags. This tagging instructs the cell's molecular destruction machine, called the proteasome, that "this protein is now waste; degrade it." The target protein is broken down. The PROTAC molecule is released and repeats the same task on another target protein — in other words, in a catalytic manner, it operates.
How Does It Differ from Conventional Targeted Therapy?
A conventional small-molecule inhibitor stays bound when it binds to a protein; the drug must remain at a certain concentration inside the cell for its effect to continue, and the protein regains its function when the drug is metabolized. A PROTAC, however, eliminates a molecule entirely; it then becomes free and continues degrading other molecules. This provides three important advantages: (1) An effect at a lower dose, (2) The potential to remain effective against mutated proteins (because even if a mutation changes the protein's shape and disrupts the inhibitor-binding site, a PROTAC can attach at a different site), (3) The ability to reach targets considered "undruggable."
The PROTAC concept was developed in 2001 at Yale University by Craig Crews and his team. In 2013, Crews founded Arvinas to bring this technology into clinical oncology. Following a 25-year scientific journey, vepdegestrant's approval on 1 May 2026 is the tangible moment when academic research moves from the laboratory to a license for clinical use.
Undisputed Superiority over Fulvestrant
VERITAC-2 (NCT05654623) was conducted as a randomized, open-label, active-controlled, multicenter phase 3 trial involving 624 adults with ER+/HER2- advanced or metastatic breast cancer who had previously received one or two lines of endocrine therapy (at least one including a CDK4/6 inhibitor). Patients were randomized in a 1:1 ratio to receive 200 mg of oral vepdegestrant once daily or 500 mg of intramuscular fulvestrant monthly . The trial's main analysis population consisted of 270 patients harboring an ESR1 mutation — detected in blood through circulating tumor DNA (ctDNA), using central or local testing.
The results revealed a statistically significant difference in progression-free survival (PFS) in the ESR1-mutant population. In the vepdegestrant group, median PFS was 5,0 months; in the fulvestrant group, median PFS was 2,1 months; the hazard ratio was 0,57 (meaning the risk of progression or death was 43% lower in the vepdegestrant group). Objective response rates also diverged markedly: 19% versus 4%. Overall survival (OS) data are not yet mature — at the time of analysis, only 16% of deaths had occurred — so we will see the OS outcome later. The trial was presented at the ASCO 2025 annual meeting and, in The New England Journal of Medicine, was published simultaneously.
The Name of a Resistance Mechanism
ER+/HER2- breast cancer accounts for approximately 70% of all breast cancers. These patients can be treated effectively for years with aromatase inhibitors (anastrozole, letrozole, exemestane) and CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib). However, resistance mutations in ESR1, the gene encoding the estrogen receptor, emerge in approximately 30-40% of patients receiving long-term aromatase inhibitor therapy. These mutations (most commonly Y537S, D538G, E380Q) activate the receptor even without estrogen; aromatase inhibition is therefore no longer sufficient.
Guardant360 CDx and Modern Precision Oncology
An important component of the VERITAC-2 trial and the FDA approval is that an ESR1 mutation is detected through circulating tumor DNA (ctDNA) in the blood. Detecting mutations in a blood sample rather than a conventional tumor biopsy is one of the most important revolutions in clinical oncology over the last five years. Testing based on ctDNA has three main advantages:
🩸 Three Advantages of ESR1 Testing with ctDNA
- 1. Old tumor tissue samples are not used. Paraffin blocks obtained years earlier did not contain an ESR1 mutation (mutations emerge during treatment); ctDNA provides an up-to-date mutational landscape.
- 2. It reflects tumor heterogeneity. Different clones may exist in different parts of the body; blood is a pool that collects DNA from all of them.
- 3. It can be repeated. Testing at regular intervals during treatment can track the emergence of new mutations — in other words, dynamic precision oncology.
Alongside Foundation Liquid CDx, Guardant360 CDx is currently one of the most widely used comprehensive genomic profiling platforms in the US. In Turkey, similar platforms (Guardant360, FoundationOne Liquid CDx, Tempus xF, Caris) are accessible for clinical use at centers such as Memorial, Acıbadem, Anadolu Sağlık, and Hacettepe — and ESR1 testing is increasingly becoming standard, especially for patients with advanced ER+ breast cancer. These platforms' costs are accessible under the international patient-payment model; SGK coverage remains limited, and access is usually obtained through an individual-use authorization process.
A New Algorithm, a New Treatment Sequence
As of 2026, the treatment algorithm for ER+/HER2- advanced or metastatic breast cancer is being updated as follows:
📋 PREVIOUS STANDARD (BEFORE 2024)
1st line: AI + CDK4/6i (palbo/ribo/abema) · After progression: Fulvestrant ± alpelisib (PIK3CA-mutant) ± everolimus · ESR1 testing optional · Monthly intramuscular injection required · Limited response rates
📋 NEW ALGORITHM (AFTER 2026)
1st line: AI + CDK4/6i (palbo/ribo/abema) · After progression: ESR1 testing with ctDNA · ESR1-mutant: Vepdegestrant (oral) · ESR1 wild-type: Fulvestrant ± alpelisib/everolimus · Better response rate, oral administration, patient adherence
QTc Prolongation and Embryofetal Toxicity
The FDA prescribing information contains two main warnings:
2. Embryofetal toxicity: The drug can cause fetal harm during pregnancy; effective contraception and interruption of breastfeeding during treatment in nursing mothers are recommended.
The recommended dose, 200 mg orally once daily, with food, is continued until disease progression or unacceptable toxicity develops. The most common side effects in clinical trials included fatigue, nausea, anemia, elevated transaminases, QTc prolongation, and diarrhea. An important advantage is the absence of local reactions related to intramuscular injections (pain and hardness at the site of fulvestrant's monthly injection).
Overall Survival Data Are Not Yet Mature
⚠️ Important Clinical Limitations
1. Overall survival (OS) data in VERITAC-2 are not yet mature; it is not certain that a PFS benefit will translate into an OS benefit. 2. The trial did not show a statistically significant PFS benefit in ESR1 wild-type patients — so fulvestrant remains the standard for patients without an ESR1 mutation. 3. Combining vepdegestrant with other targeted agents such as a CDK4/6 inhibitor, alpelisib, or everolimus remains in clinical trials (VERITAC-3 and others); under the current FDA approval, monotherapy is the approved use. 4. Fulvestrant's PFS value (2,1 months) lies at the lower end of historical data — raising some questions about the fulvestrant arm (the limits of fulvestrant monotherapy's effectiveness after CDK4/6i). 5. There is no access in Turkey yet — following FDA approval, the drug will undergo European Medicines Agency (EMA) and Turkish Ministry of Health procedures; early access may be possible through individual-use authorization.
The PROTAC Era Is Just Beginning
Vepdegestrant is the first PROTAC drug approved for clinical use. However, this class has a much broader future ahead. Other PROTAC candidates currently in clinical phases include:
Other PROTAC Drugs in Clinical Development (2026)
- ARV-766 (luxdegalutamide): Androgen receptor PROTAC, phase 3 in metastatic castration-resistant prostate cancer (Arvinas)
- Bavdegalutamide (ARV-110): AR PROTAC (Arvinas), prostate cancer
- NX-2127, NX-5948: BTK PROTACs, chronic lymphocytic leukemia (Nurix)
- KT-474, KT-413: IRAK4 PROTACs (Kymera), autoimmune and hematologic malignancies
- BCL6, STAT3, IKZF2 PROTACs: Agents targeting transcription factors previously considered "undruggable"
- CDK9, CDK2 PROTACs: Under investigation in solid tumors
The modern oncology research ecosystem hopes to use PROTACs to target two major protein classes that conventional inhibitors cannot reach: (1) transcription factors without an active site (MYC, β-catenin, p53 mutants), (2) conventional targets that acquire drug resistance through mutation (such as BCR-ABL T315I). Vepdegestrant's approval is the first clinical proof of this vision.
⚡ WHY DOES IT MATTER?
Vepdegestrant is the first PROTAC drug approved by the FDA for clinical use — the historical moment when "targeted protein degradation" (TPD) technology moves from an academic concept into clinical reality. For ESR1 resistance mutations that emerge after long-term aromatase inhibitor therapy in approximately 30-40% of patients with ER+/HER2- breast cancer, an oral, targeted, and clinically superior treatment option is now being offered for the first time. The same-day approval of Guardant360 CDx as a companion diagnostic also demonstrates how firmly liquid biopsy-based precision oncology has become established in standard practice.
✅ STRENGTHS
In the VERITAC-2 phase 3 trial, in ESR1-mutant ER+/HER2- advanced breast cancer, median PFS was 5,0 vs 2,1 months compared with fulvestrant (HR 0,57, p=0,0001); ORR was 19% vs 4% — a statistically robust and clinically meaningful benefit. Oral administration offers a major advantage for patient adherence over fulvestrant's monthly intramuscular injection. Testing for ESR1 based on ctDNA does not require a current tumor tissue biopsy. Because the PROTAC mechanism can also degrade mutant proteins, it partially bypasses conventional resistance pathways. FDA approval was granted 1 month before the planned date.
⚠️ LIMITATIONS
Overall survival (OS) data are not yet mature — at the time of analysis, 16% of deaths had occurred. No significant benefit was demonstrated in ESR1 wild-type patients, so the approval is only for the ESR1-mutant subgroup. PFS in the fulvestrant arm (2,1 months) is at the lower end of historical data. QTc prolongation requires monitoring. There is no access in Turkey yet — access will depend on European and Turkish approval procedures or individual-use authorization. Combination use (with CDK4/6i, mTOR, and PI3K inhibitors) remains in clinical trials; the drug was approved as monotherapy.
🩺 IMPLICATIONS FOR CLINICAL PRACTICE
In ER+/HER2- advanced breast cancer, ESR1 testing is now becoming standard for every patient whose disease progresses after an aromatase inhibitor + CDK4/6 inhibitor. Vepdegestrant should be preferred in patients found to have an ESR1 mutation; for wild-type patients, fulvestrant ± alpelisib/everolimus remain options. Testing based on ctDNA — especially for dynamic monitoring during treatment — is becoming routine practice at centers such as Memorial, Acıbadem, and Anadolu Sağlık. For patients from the Turkic republics and other international patients, the individual-use authorization process may provide an important route to drug access.
❓ FUTURE QUESTIONS
When the OS data from VERITAC-2 mature, will the PFS benefit translate into a true survival benefit? Can combinations of vepdegestrant with CDK4/6 inhibitors (TACTIVE-U) and alpelisib/everolimus be moved into early-stage or first-line treatment? Will it have a role in early-stage adjuvant use (high-risk ER+/HER2- early-stage breast cancer, even in the ESR1 wild-type cohort)? The other targets against which PROTACs may demonstrate clinical benefit — especially transcription factors considered "undruggable" — will be among the most exciting areas of clinical research over the next 5 years. How quickly will the reimbursement process move forward in Turkey, and how will access for international patients take shape?
Sources
- U.S. Food and Drug Administration. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. 1 May 2026. Oncology (Cancer)/Hematologic Malignancies Approval Notifications.
- Hamilton EP, Petit T, Pistilli B, et al. VERITAC-2: vepdegestrant versus fulvestrant in ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. The New England Journal of Medicine 2025; simultaneous publication, ASCO 2025.
- Gough SM, Flanagan JJ, Teh J, et al. Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clinical Cancer Research 2024;30(16):3549.
- Sakamoto KM, Kim KB, Kumagai A, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences 2001;98(15):8554-8559. (The original PROTAC publication by Crews and his team.)
- Liu Z, Hu M, Yang Y, et al. An overview of PROTACs: a promising drug discovery paradigm. Molecular Biomedicine 2022;3(1):46.
- Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery 2022;21(3):181-200.
- Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Research 2021;23(1):85.
- Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, HER2-negative, advanced breast cancer (EMERALD trial). Journal of Clinical Oncology 2022;40(28):3246-3256. (Reference for earlier clinical development of an ESR1 SERD.)
- Arvinas, Inc. NDA submission and FDA acceptance announcements, 2025. Press releases, ir.arvinas.com.
- Guardant Health. Guardant360 CDx FDA companion diagnostic approval for vepdegestrant ESR1 mutation testing, 1 May 2026.
This article is intended for medical news/information purposes and does not provide individual treatment guidance. Treatment selection for patients with ER+/HER2- advanced or metastatic breast cancer should take place in a multidisciplinary oncology board, considering the patient's clinical condition, previous treatment history, molecular profile, and other biomarkers. Editor's note: Access to vepdegestrant in Turkey depends on completion of European Medicines Agency (EMA) and Turkish Ministry of Health procedures; early access may be possible through individual-use authorization. Testing for ESR1 based on ctDNA has been made available for clinical use at centers such as Memorial, Acıbadem, Anadolu Sağlık, and Hacettepe. The article is based on the FDA approval notification dated 1 May 2026 and the ASCO 2025 and NEJM publication data from the VERITAC-2 (NCT05654623) trial.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.